Stopping Heavy Periods Project

Abnormal Uterine Bleeding Clinical Trial

— SHiPP  

Official title:

Levonorgestrel Intrauterine System Versus Oral Contraceptives for Heavy Menses

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02002260
• Other study ID #: R01HD074751
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 2013
• Est. completion date: December 31, 2021

Study information

• Verified date: July 2021
• Source: Women and Infants Hospital of Rhode Island
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized clinical trial comparing the effectiveness of the levonorgestrel intrauterine system (LNG-IUS) to combined oral contraceptives (COCs) for improving quality of life among women who report heavy menstrual bleeding.

Description:

This study is designed to be conducted within the context of a patient's standard/usual/typical care from their primary gynecologic care provider. We hypothesize that, compared to COCs, the LNG-IUS will be more effective at improving bleeding-related quality of life at 6 months and one year. To test this hypothesis, we plan to enroll 59 women from several sites who present for gynecologic care and self-report heavy menstrual bleeding into a RCT comparing LNG-IUS to COCs. The eligible study population includes women with heavy menstrual bleeding secondary to ovulatory disorders (AUB-O) or endometrial hemostatic disorders (AUB-E). Women meeting study eligibility will be randomized to receive LNG-IUS or COCs. Main study outcomes will be obtained at 6 weeks, 3 months, 6 months, and 1 year.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 59
• Est. completion date: December 31, 2021
• Est. primary completion date: June 16, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 51 Years

Eligibility

Inclusion Criteria:

• Self-reported heavy menstrual bleeding

• Age 18-51 years

• Etiology of heavy menstrual bleeding from either ovulatory disorders (AUB-O) or endometrial hemostatic disorders (AUB-E)

Exclusion Criteria:

• Plan pregnancy in the next year

• Menopausal

• Currently has a copper IUD in place

• History of ablation or hysterectomy or have any contraindications to COCs or LNG-IUS

Related Conditions & MeSH terms

• Abnormal Uterine Bleeding
• Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
• Abnormal Uterine Bleeding, Ovulatory Dysfunction
• Hemorrhage
• Uterine Hemorrhage

Intervention

Device:
• Levonorgestrel intrauterine system

Drug:
• Combined oral contraceptives

Locations

Country	Name	City	State
United States	Gynecologic practices affiliated with Women and Infants Hospital	Providence	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Women and Infants Hospital of Rhode Island

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Menstrual Bleeding Questionnaire	We will measure bleeding-specific quality of life using the Menstrual Bleeding Questionnaire (MBQ), a validated tool to assess bleeding-related quality of life, which is the most important outcome for patients and for clinicians treating this symptom. We will measure MBQ score at randomization, and at 6 weeks, 3 month, 6 months, and 12 months post-randomization for both groups	Completed 5 times over a one year time period
Secondary	Treatment Failure	The goal of treating heavy menstrual bleeding is to utilize a treatment option that improves patient quality of life and avoids surgical intervention. We will look at treatment failure two different ways. We will determine the overall proportion of participants who discontinued their assigned treatment (opted for no treatment or chose a different treatment option, including surgery) and subset that opted for surgical intervention (endometrial ablation or hysterectomy) during the study period. This information will be recorded by the primary gynecologic provider (physical examination and physician form), by participants (interval health history form), and by the research team (medical record review).	Information collected at four time points during a one year period post randomization